Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.34 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.34 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.34 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822134 | 0.92 | ALDH1A1 (0.44) | ALDH1A1NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL2201853 | 0.88 | ALDH1A1 (0.37) | ALDH1A1NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL2201604 | 0.87 | CYP3A4 (0.39) | ALDH1A1NPC1RAB9ACYP1A1CYP1B1 | |
| SCHEMBL16803093 | 0.86 | KDM1A (0.40) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL11258618 | 0.82 | NPC1 (0.38) | ALDH1A1NPC1RAB9ACYP19A1HPGD | |
| SCHEMBL18063537 | 0.80 | HTR2C (0.51) | NPC1RAB9ACYP19A1KMT2AHTR2C | |
| SCHEMBL15709396 | 0.80 | CHRM1 (0.34) | ALDH1A1NPC1RAB9AHPGDKMT2A | |
| SCHEMBL4723773 | 0.78 | MAOA (0.48) | NPC1RAB9AHPGDKMT2AHTR2C | |
| SCHEMBL8992843 | 0.75 | BRD4 (0.39) | ALDH1A1NPC1RAB9AKMT2ACYP3A4 | |
| SCHEMBL6347223 | 0.75 | NPC1 (0.33) | ALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846402-B1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | MAP4K2, ABL1, MAP4K3 | ALDH1A1 2786/4885NPC1 4778/4885RAB9A 1269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.